SCHEMBL3328880

SCHEMBL3328880

CCOC(=O)C1=C(C)NC2=C(C(=O)CCC2)C1c1ccc(Cl)cc1Cl

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 14/20 0.65
ALDH1A1 P00352 12/20 0.64
HPGD P15428 6/20 0.64
GAA P10253 4/20 0.64
HTT P42858 2/20 0.64
ALOX12 P18054 2/20 0.64
NPSR1 Q6W5P4 2/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
HSD17B10 Q99714 7/20 0.61
TSHR P16473 1/20 0.61
MAPK1 P28482 1/20 0.60
CASP1 P29466 3/20 0.59
CASP7 P55210 3/20 0.59
BAP1 Q92560 1/20 0.57
TP53 P04637 1/20 0.57
POLB P06746 1/20 0.57
GALR3 O60755 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3323328 0.87 KDM4E (0.58) KDM4EALDH1A1HPGDGAAHTT
SCHEMBL3320549 0.85 KDM4E (0.77) KDM4EALDH1A1HPGDGAAHTT
SCHEMBL3324672 0.85 KDM4E (0.63) KDM4EALDH1A1HPGDGAAHTT
SCHEMBL3016247 0.81 MAPK1 (0.70) KDM4EALDH1A1HPGDGAAALOX12
SCHEMBL13333342 0.81 ALDH1A1 (0.71) KDM4EALDH1A1HPGDGAAHTT
SCHEMBL4260123 0.80 KDM4E (0.67) KDM4EALDH1A1HPGDGAAHTT
SCHEMBL3323749 0.80 KDM4E (0.86) KDM4EALDH1A1HPGDGAAHTT
SCHEMBL3249662 0.80 KDM4E (0.69) KDM4EALDH1A1HPGDGAAHTT
SCHEMBL3324905 0.80 ALDH1A1 (0.71) KDM4EALDH1A1HPGDGAANPSR1
SCHEMBL15765866 0.80 KDM4E (0.72) KDM4EALDH1A1HPGDGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION APP, MAPT, PSEN1 KDM4E 4115/4885ALDH1A1 2615/4885HPGD 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.